Accelovance, Immunicum partner to advance cancer vaccine


Sweden’s Immunicum has signed a transatlantic partnership with Rockville, MD’s Accelovance to further its lead cancer immune primer Intuvax through U.S. tests in kidney cancer and melanoma.

The arrangement will see Accelovance provide clinical monitoring, data management, biostatistics and safety services for the trials, while Immunicum will oversee quality standards regarding patient safety and compliance. Immunicum additionally gets access to the CRO’s Preferred Sites Network through cooperation with the Midwest Melanoma Partnership.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

The partners will work with Intuvax, a dendritic cell vaccine that Immunicum hopes can elicit an inflammatory response triggering the activation of cytotoxic T lymphocytes to fight tumors.

Immunicum also stands to gain from the contributions of Dr. Arkadiusz Dudek, director of the Oncology Clinical Trials Office at the University of Illinois' College of Medicine, who will serve as lead investigator in the U.S.

"We believe we have found the best collaboration scenario to aid us with our company's next step in clinical development,” Immunicum CEO Jamal El-Mosleh said in a statement. “This new agreement underscores our commitment to researching the effectiveness of Intuvax as a cancer immune primer in additional indications and expands our research capabilities tremendously.”

Founded in 2005 with locations around the U.S. and the world, Accelovance has expertise in the areas of oncology, vaccines and general medicine. Immunicum, for its part, is aiming to create “the blue-print for the world's first personalized, off-the-shelf affordable cancer treatment” and plans to license its tech to pharma or biotech companies in the field.

- here’s the release


Suggested Articles

A new survey by Clinical Research IO has found that nearly one-quarter of polled trial investigators have stopped enrolling new patients.

CRO Charles River Laboratories has signed up to use a preclinical digital pathology software-as-a-service platform from Deciphex.

In March, the FDA urged biopharmas and CROs to take a virtual approach to clinical trials in reaction to COVID-19 and the attempt to slow its spread.